

FINANCIAL SUMMARY


A summary of the published results and assets, liabilities and minority interests of the Group for the last five financial years, as extracted from the audited financial statements and reclassified as appropriate, is set out below. This summary does not form part of the audited financial statements.

	2006 HK\$'000	2005 HK\$'000	2004 HK\$'000	2003 HK\$'000	2002 HK\$'000
CONTINUING OPERATIONS					
TURNOVER	734,652	756,073	664,296	456,089	342,610
Cost of sales	(138,788)	(139,418)	(133,163)	(105,872)	(73,201)
Gross profit	595,864	616,655	531,133	350,217	269,409
Other income and gains	91,486	28,599	7,063	8,154	3,389
Selling and distribution costs	(327,720)	(310,609)	(253,390)	(176,167)	(152,372)
Administrative expenses	(121,802)	(110,866)	(101,885)	(79,396)	(53,550)
Other expenses	(31,254)	(42,224)	(33,382)	(18,593)	(13,349)
Finance costs	(2,205)	(2,729)	(1,050)	(843)	(418)
Share of profit of an associate	704	–	–	–	–
PROFIT BEFORE TAX AND BEFORE FAIR VALUE ADJUSTMENT FOR DERIVATIVE FINANCIAL INSTRUMENT	205,073	178,826	148,489	83,372	53,109
Fair value adjustment	–	(66,315)	–	–	–
PROFIT BEFORE TAX	205,073	112,511	148,489	83,372	53,109
Tax	(22,106)	(18,311)	(15,407)	(11,625)	(9,540)
PROFIT FOR THE YEAR FROM CONTINUING OPERATIONS	182,967	94,200	133,082	71,747	43,569
DISCONTINUED OPERATION					
Profit for the year from a discontinued operation	–	152,213	152,129	78,209	74,842
Gain on disposal of subsidiaries	–	1,406,191	–	–	–
Total profit for the year from a discontinued Operation	–	1,558,404	152,129	78,209	74,842
PROFIT FOR THE YEAR	182,967	1,652,604	285,211	149,956	118,411
Attributable to:					
Equity holders of the parent	141,172	1,532,929	168,485	81,636	57,369
Minority interests	41,795	119,675	116,726	68,320	61,042
	182,967	1,652,604	285,211	149,956	118,411
TOTAL ASSETS	2,215,110	2,140,222	950,535	787,244	593,986
TOTAL LIABILITIES (exclude convertible bonds)	(183,611)	(164,978)	(239,845)	(215,531)	(124,653)
CONVERTIBLE BONDS	–	–	(42,900)	(78,000)	(46,800)
NET ASSETS	2,031,499	1,975,244	667,790	493,713	422,533
MINORITY INTERESTS	(122,937)	(121,997)	(211,716)	(156,348)	(129,725)

FINANCIAL SUMMARY


SALES GROWTH OF CONTINUING OPERATIONS

FIG. 1.2



GROWTH OF PROFIT FROM CONTINUING OPERATIONS

FIG. 1.3




* Profit before fair value adjustment for derivative financial instrument

FINANCIAL SUMMARY


SALES GROWTH OF BLOCKBUSTER PRODUCTS

FIG.1.4




NET ASSET VALUE

FIG.1.5



CASH AND CASH EQUIVALENTS


FIG.1.6



FINANCIAL SUMMARY

TURNOVER BY THERAPEUTIC CATEGORIES


FIG. 1.7



TURNOVER BY NEW PRODUCTS WITH GREAT POTENTIAL (2006)

FIG. 1.8

(HK\$'000)



- A Tianqingganping enteric capsules (launched in May 2004)
- B Tianqingganmei injections (launched in November 2005)
- C Mingzheng capsules (launched in July 2006)
- D Tianqinggan injections (launched in April 2004)
- E Tianqingyitai injections (launched in January 2005)
- F Kaifen injections (launched in January 2005)
- G Taibai sustained release tablets (launched in May 2004)